Effectiveness and safety of hydrogen inhalation as an adjunct treatment in Chinese type 2 diabetes patients: A retrospective, observational, double-arm, real-life clinical study.
Ziyi Zhao, Hongxiang Ji, Yunsheng Zhao, Zeyu Liu, Ruitao Sun, Yuquan Li, Tongshang Ni · Frontiers in endocrinology · 2022
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 2 patients, compared to the control group, participants in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7 mg/dL), total cholesterol (-12.9 mg/dL vs -4.4 mg/dL), HOMA-IR (-0.76 vs -0.17) and HOMA-β (8.2% vs 1.98%) with all p 1% reduction at the follow-up period was higher in the HI group. Patients in the control group were more likely to attain HbA1c ≥ 9%. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence glucose regulation and metabolic health.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 2 patients. Compared to the control group, participants in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7 mg/dL), total cholesterol (-12.9 mg/dL vs -4.4 mg/dL), HOMA-IR (-0.76 vs -0.17) and HOMA-β (8.2% vs 1.98%) with all p 1% reduction at the follow-up period was higher in the HI group. Patients in the control group were more likely to attain HbA1c ≥ 9%.
What the Researchers Studied
The researchers studied 2 patients. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Compared to the control group, participants in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7 mg/dL), total cholesterol (-12.9 mg/dL vs -4.4 mg/dL), HOMA-IR (-0.76 vs -0.17) and HOMA-β (8.2% vs 1.98%) with all p 1% reduction at the follow-up period was higher in the HI group. Patients in the control group were more likely to attain HbA1c ≥ 9%.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence glucose regulation and metabolic health and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 2 patients. The reported sample size was 1088. The study used a randomized human clinical trial.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.